Types of material transfer agreement fall into two overlapping categories: direction of transfer (one-way versus two-way) and nature of the parties (academic/non-profit versus commercial-use). Choosing the wrong category adds weeks of unnecessary negotiation to a simple exchange, or leaves an institution exposed on intellectual property and liability in a complex one. A material transfer agreement (MTA) is a contract that governs the transfer of tangible research materials — cell lines, plasmids, reagents, antibodies, animal models, or genetic constructs — between a provider and a recipient, setting terms for permitted use, publication, and downstream rights.
- What is a material transfer agreement, and why does type matter?
- One-way vs two-way MTAs: what is the difference?
- Academic/non-profit vs commercial-use MTAs: how do the terms differ?
- Which standard templates exist, and how do you choose the right one?
- Frequently asked questions
- Implications and outlook for research administrators
What is a material transfer agreement, and why does type matter?
A material transfer agreement is the legal instrument accompanying the physical movement of a research material between organisations. It records who owns the original material, what the recipient may do with it, who owns derivatives the recipient creates, and what happens if the material leads to a publication or invention.
Institutions do not use one template for every transfer. The right MTA type depends on two independent variables: direction of the exchange, and the nature of the parties — non-profit or commercial. Mismatching the template to either variable is a common cause of avoidable negotiation delay.
One-way vs two-way MTAs: what is the difference?
A one-way MTA covers a single direction of transfer: one provider sends material to one recipient, who accepts the provider’s terms. Most institutional MTAs are one-way and are further split into two sub-types depending on which side of the transaction the institution sits on.
- Incoming MTA — the institution is the recipient. The priority is understanding and accepting the provider’s restrictions: permitted research use, any prohibition on commercial use, and publication or embargo terms.
- Outgoing MTA — the institution is the provider. The priority shifts to protecting the institution’s own intellectual property, limiting liability for the material’s performance, and controlling further distribution by the recipient.
A two-way (or reciprocal) MTA is used when both parties send materials to each other, typically in an active collaboration where each lab holds a resource the other needs. Rather than negotiate two separate one-way agreements, the parties combine both transfers into a single reciprocal agreement with symmetric obligations. This is administratively efficient but requires both sides to specify their respective materials and restrictions with equal precision — asymmetric two-way MTAs are a frequent source of later disputes over derivative rights.
| MTA type | Direction | Typical parties | Primary administrative focus |
|---|---|---|---|
| Incoming (one-way) | Provider → institution | Academic-to-academic or vendor-to-academic | Compliance with provider’s use and publication restrictions |
| Outgoing (one-way) | Institution → external recipient | Academic-to-academic or academic-to-industry | IP retention, liability limitation, distribution control |
| Two-way / reciprocal | Bidirectional | Collaborating academic labs | Symmetric terms for both transferred materials |
| Academic/non-profit | Either direction | Non-profit-to-non-profit | Non-commercial research use only; minimal negotiation |
| Commercial-use | Either direction | At least one for-profit party | IP ownership, licensing options, publication delay, indemnification |
Academic/non-profit vs commercial-use MTAs: how do the terms differ?
The second axis of classification is the nature of the parties, and it changes negotiation complexity more than direction does. A biological material transfer agreement between two non-profit universities is usually a light-touch document; the same transfer involving a commercial partner routinely takes months longer to close.
Academic and non-profit MTAs exist to facilitate open scientific exchange. The US National Institutes of Health (NIH) has stated that unique research resources arising from NIH-funded work should be shared on terms no more restrictive than its own model agreements, because repeated case-by-case negotiation between non-profits delays the point at which a research tool reaches the laboratory bench. These agreements typically restrict use to non-commercial research, require no royalty, and rarely need individual negotiation once a standard template is adopted.
Commercial-use MTAs — where a for-profit company is provider, recipient, or both — carry additional, negotiated terms that a non-profit template does not anticipate:
- Intellectual property rights over inventions made using the transferred material, including whether the provider retains an option to license.
- Publication rights, including any pre-publication review period the commercial party can invoke to protect confidential information.
- Scope of permitted use, distinguishing internal research from development toward a commercial product, which may trigger the need for a separate licence agreement.
- Indemnification and liability allocation, which non-profit-to-non-profit templates typically waive or cap at a nominal level.
A material transfer agreement policy should specify, in advance, which of these terms are non-negotiable defaults and which require case-by-case legal review — allowing routine academic MTAs to clear in days, reserving negotiation capacity for the commercial-use cases where it is genuinely needed.
Which standard templates exist, and how do you choose the right one?
Four template families cover the great majority of transfers, and matching a transfer to the correct family is the fastest route to a signed agreement.
- NIH Simple Letter Agreement (SLA), published in 1995 by the NIH, is a one-page model for low-risk, non-commercial transfers of routine research materials between non-profit institutions.
- Uniform Biological Material Transfer Agreement (UBMTA), also introduced in 1995, is the master agreement signed once by an institution; individual transfers under it use a short “Implementing Letter” rather than a fresh negotiation, and it is the standard route for a two-way material transfer agreement between two UBMTA-signatory non-profits.
- AUTM Model MTAs extend the UBMTA framework to materials — and non-US institutions — outside the UBMTA’s original definition of biological material; a 2011 AUTM member survey found low adoption of standard templates was itself a major cause of unnecessary delay, which the toolkit’s decision tree was built to address.
- FAO Standard Material Transfer Agreement (SMTA), adopted by the Governing Body of the International Treaty on Plant Genetic Resources for Food and Agriculture in 2006, is a distinct global instrument governing plant genetic resources held in the Treaty’s Multilateral System, with mandatory benefit-sharing terms that have no equivalent in the UBMTA or NIH templates.
To choose: start by identifying direction (one-way or two-way) and party type (non-profit or commercial). If both parties are non-profit and the material is biological, default to the UBMTA or SLA. If a commercial party is involved, route the transfer to legal review rather than a standard template. If the material is a plant genetic resource in the Multilateral System, the FAO SMTA applies regardless of the parties’ institutional type — a distinction general MTA guidance frequently omits.
Frequently asked questions
What is a material transfer agreement?
A material transfer agreement is a contract governing the transfer of tangible research materials — such as cell lines, plasmids, reagents, or animal models — between a provider and a recipient. It sets terms for permitted use, ownership of derivatives, publication rights, and liability, and is negotiated before the physical material is shipped.
What is the difference between an MTA and an NDA?
An NDA (non-disclosure agreement) protects confidential information exchanged between parties, while an MTA governs the physical transfer and permitted use of a tangible material. The two are often signed together — an NDA may protect data about the material, while the MTA governs the material itself — but neither substitutes for the other.
What is the standard material transfer agreement?
The Standard Material Transfer Agreement (SMTA) is the FAO instrument used specifically for plant genetic resources held under the International Treaty on Plant Genetic Resources for Food and Agriculture’s Multilateral System. It is distinct from the UBMTA used for general biological materials and includes mandatory benefit-sharing obligations tied to the Treaty.
Implications and outlook for research administrators
Institutions that map every incoming request against this taxonomy before drafting — direction first, party type second, then template — process the majority of routine biological material transfer agreement requests without individual legal review. That triage is what standard templates like the UBMTA and NIH SLA were designed to enable, and what a written material transfer agreement policy should formalise as institutional default practice.
The remaining minority — commercial-use transfers, cross-border plant genetic material, and asymmetric two-way exchanges — is where administrative time should concentrate, since these are the categories where the wrong template creates the greatest downstream IP and compliance risk. As collaborations increasingly span academic, industry, and international-treaty jurisdictions at once, classifying a transfer correctly at intake, rather than after a dispute arises, remains the most effective control a research administration office can apply.